source
- Revolution Medicines’ pancreatic cancer drug Rasonque priced at $39,800 a month, analysts predict blockbuster sales after swift FDA approvalRevolution Medicines announced that its new pancreatic cancer therapy, Rasonque, received FDA approval in a rapid review process. The drug is priced at $39,800 for a 30-day supply, which translate…
- Moderna raises $2 billion after Phase 3 success of its algorithm-driven personalized cancer vaccine with MerckModerna announced a $2 billion convertible debt financing, a move that follows the Phase 3 success of its personalized cancer vaccine developed with Merck. The vaccine relies on software that scan…STAT · 17d agoPositive readoutPositive